Rates of repeat EGD in nondiabetic adults with glucagon-like peptide-1 receptor agonist prescription: a retrospective matched cohort study.

Data on endoscopic outcomes in adults without diabetes who are taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) are limited. Therefore, we compared repeat EGD in this population with those not taking GLP-1RAs using a retrospective matched case-control study. Using the TriNetX health research platform (Cambridge, Mass, USA), we analyzed adults with a body mass index ≥27 kg/m² without diabetes who underwent diagnostic EGD. The study group included individuals with ≥3 GLP-1RA prescriptions and undergoing EGD ≥30 days after the initial GLP-1RA prescription. The control group included individuals who were never prescribed GLP-1RAs but had an EGD after the prescription of other weight loss medications. Outcomes were compared using the risk ratio (RR) in matched cohorts. No significant difference in repeat EGD (5.4% vs 4.2%; RR, 1.28; 95% confidence interval [CI],.95-1.71) or new diagnosis of gastroparesis (1.1% vs.6%; RR; 2.00; 95% CI,.94-4.27) was noted between the groups. GLP-1RAs may not substantially increase the risk of repeat endoscopy in individuals without diabetes. [ABSTRACT FROM AUTHOR]